Dergiler / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 3

Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study

Sayfa
266–270
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

High rates ofTE-defined fibrosis and steatosis in our sample reflect the presence of an elevated mean BMI.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Non-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus (T2DM).
📊
Temel Bulgular & Veri:The aim of thepresent study was to investigate the potential usefulness of transient elastography (TE), which is a technique that allows measuringboth fibrosis and liver fat content simultaneously, as a screening tool for hepatic involvement in Turkish patients with T2DM.Materials and Methods: We obtained liver stiffness measurements (LSMs, as a measure of fibrosis) and controlled attenuation parameter (CAP, as a marker of steatosis) in 124 (46 males and 78 females; mean body mass index (BMI): 33.2±6.6 kg/m2) Turkish patients withT2DM.
💡
Sonuç & Katkı:High rates ofTE-defined fibrosis and steatosis in our sample reflect the presence of an elevated mean BMI.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Non-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus (T2DM). The aim of thepresent study was to investigate the potential usefulness of transient elastography (TE), which is a technique that allows measuringboth fibrosis and liver fat content simultaneously, as a screening tool for hepatic involvement in Turkish patients with T2DM.Materials and Methods: We obtained liver stiffness measurements (LSMs, as a measure of fibrosis) and controlled attenuation parameter (CAP, as a marker of steatosis) in 124 (46 males and 78 females; mean body mass index (BMI): 33.2±6.6 kg/m2) Turkish patients withT2DM. The prevalence rates of overweight, obesity, and metabolic syndrome in our sample were 28.2%, 64.5%, and 77.4%, respectively.Probe-specific LSM cut-off values were used to define advanced fibrosis (≥F3) and cirrhosis (F4) (M probe: F3=9.6-11.4 kPa, F4 ≥11.5 kPaand XL probe: F3=9.3-10.9 kPa, F4 ≥11.0 kPa). Mild, moderate, and severe steatosis were defined as CAP 222-232 dB/m, CAP 233-289dB/m, and CAP ≥290 dB/m, respectively.Results: Advanced fibrosis and cirrhosis were identified in 21 (16.9%) and 10 (8.0%) patients, respectively. TE-defined hepatic steatosis(CAP>222 dB/m) was detected in 117 (94.3%) patients. Mild, moderate, and severe steatosis were identified in 0, 29, and 88 patients,respectively.Conclusion: TE is a useful non-invasive imaging modality to screen for liver involvement in Turkish patients with T2DM. High rates ofTE-defined fibrosis and steatosis in our sample reflect the presence of an elevated mean BMI.

🔖

Bu Makaleye Atıf Yap

DEMİR, M., DEYNELİ, O., YILMAZ, Y. (2019). Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 3, 266–270. https://ajindex.com/articles/409270

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42. [CrossRef] Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65: 1557-65. [CrossRef] Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab 2015; 19: 597- 601. [CrossRef] Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012; 2012: 145754. Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci 2014; 11: 925-35. [CrossRef] Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47: 1363-70. [CrossRef] Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 6821-5. [CrossRef] Maida M, Macaluso FS, Salomone F, Petta S. Non-invasive assessment of liver injury in non-alcoholic fatty liver disease: a review of literature. Curr Mol Med 2016; 16: 721-37. [CrossRef] Brener S. Transient elastography for assessment of liver fibrosis and steatosis: an evidence-based analysis. Ont Health Technol Assess Ser 2015; 15: 1-45.
  2. Tsai E, Lee TP. Diagnosis and evaluation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography. Clin Liver Dis 2018; 22: 73- 92. [CrossRef] Sporea I, Mare R, Lupușoru R, et al. Liver stiffness evaluation by transient elastography in type 2 diabetes mellitus patients with ultrasound-proven steatosis. J Gastrointestin Liver Dis 2016; 25: 167-74.
  3. Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016; 65: 1359-68. [CrossRef] Chon YE, Kim KJ, Jung KS, et al. The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. Yonsei Med J 2016; 57: 885-92. [CrossRef] Roulot D, Roudot-Thoraval F, NK